Departamento de Medicina Preventiva, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.
Departamento de Medicina Preventiva, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.
Vaccine. 2023 Feb 10;41(7):1319-1332. doi: 10.1016/j.vaccine.2023.01.015. Epub 2023 Jan 25.
To identify the main cost components included in the economic evaluations of measles outbreaks, their items and cost drivers, and evaluate the quality of costing methodology, analyzing the key features that may affect the validity of these studies in countries with different income levels.
We systematically searched multiple databases EMBASE, MEDLINE (via PubMed), Biblioteca Virtual em Saúde do Ministério da Saúde (BVS MS), NHS Economic Evaluation Database (NHS EED) and NHS Health Technology Assessment (NHS HTA) (via The Centre for Reviews and Dissemination Library - CRD), and EconLit, SCOPUS, and Web of Science, selecting cost analysis and cost of illness studies (COI) of measles outbreaks. Two independent reviewers screened articles for relevance and extracted the data. The quality of costing methods was assessed using a guide to critical evaluation of COI studies. We performed a qualitative narrative synthesis.
Twenty-two studies were reviewed. Most studies evaluated outbreaks that occurred from 2011 to 2013 and 2017 to 2019. Total costs varied from $40,147 to $39.3 million. Per case cost varied from $168 to $49,439. The main drivers of measles outbreak costs were outbreak response, personnel, and productivity losses. Most studies (20/22) did not report the costing methodology adopted, the degree of disaggregation used in the identification and measurement of resource and costs components and the method for the valuation of resource and cost components.
The quality of the costing methodology, its transparency and accuracy are essential to the validity of these studies results and their potential use to allocate public health resources in the most efficient manner and to inform measles outbreak control strategies, with rapid and effective response.
确定麻疹暴发经济评估中包含的主要成本构成部分、其项目和成本驱动因素,并评估成本核算方法的质量,分析可能影响不同收入水平国家这些研究有效性的关键特征。
我们系统地检索了多个数据库,包括 EMBASE、MEDLINE(通过 PubMed)、巴西卫生部虚拟图书馆(BVS MS)、英国国家卫生服务经济评估数据库(NHS EED)和英国国家卫生技术评估(NHS HTA)(通过 The Centre for Reviews and Dissemination Library - CRD),以及 EconLit、SCOPUS 和 Web of Science,以选择麻疹暴发的成本分析和疾病成本研究(COI)。两名独立评审员对文章的相关性进行筛选并提取数据。使用 COI 研究关键评估指南评估成本核算方法的质量。我们进行了定性叙述性综合分析。
共审查了 22 项研究。大多数研究评估了 2011 年至 2013 年和 2017 年至 2019 年发生的暴发。总费用从 40,147 美元到 3930 万美元不等。每例成本从 168 美元到 49439 美元不等。麻疹暴发成本的主要驱动因素是暴发应对、人员和生产力损失。大多数研究(20/22)未报告所采用的成本核算方法、资源和成本构成部分识别和测量的细化程度以及资源和成本构成部分估值方法。
成本核算方法的质量、透明度和准确性对于这些研究结果的有效性及其潜在用途至关重要,这些研究结果可以以最有效的方式分配公共卫生资源,并为麻疹暴发控制策略提供信息,以便快速有效地做出反应。